Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04932434 · ClinicalTrials.gov registry record · Phase 2
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
A Phase 2 study, sponsored by Joshua Woolley, MD, PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04932434 is a Phase 2 study that has completed, run by Joshua Woolley, MD, PhD. The registered enrollment target is 12 participants.
The verdict
NCT04932434, a Phase 2 study, has completed, sponsored by Joshua Woolley, MD, PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
Interventions
- DRUG Psilocybin therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-08-15 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04932434
The ClinicalTrials.gov registry entry for NCT04932434 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joshua Woolley, MD, PhD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin therapy is the first listed.
NCT04932434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04932434 about?
NCT04932434 is a clinical study titled "Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease". The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
What is the current status of trial NCT04932434?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-08-15. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT04932434?
The interventions under investigation include: Psilocybin therapy (DRUG).
Who is sponsoring clinical trial NCT04932434?
This trial is sponsored by Joshua Woolley, MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.